Price dispute blocks costly cancer drug in Canada
One of the world’s most costly cancer drugs will not be marketed in Canada because of a price dispute between the drug’s distributor and the federal government.
The colorectal cancer drug Erbitux, which was approved by Health Canada nine months ago, will not be launched after distributor Bristol Myers Squibb Canada could not agree on a price with the federal Patented Medicine Prices Review Board., The Globe and Mail reports.
…..


Tina Radcliffe spent ten years as a Oncology Certified R.N. working with in-patients on oncology and med-surg units. She also has a background in home health and geriatrics. Her other experiences include ... .. 
































